





2024 ASTRO Posters and Presentations



Scarlett Acklin-Wehnert, MD • PQA 03 • September 30 • 8-9 a.m.

Dosimetric Outcomes with the Addition of Interstitial Needles in HDR Brachytherapy for Non-Bulky Cervical Tumor




Mark Chen, MD, PhD • PQA 02 • September 29 • 4:45-6 p.m.

Improving Liver SBRT Target Localization with Hybrid MRI/CBCT Technology

PQA 04 • September 30 • 10:45 a.m.-12 p.m.

Impact of KEAP1/NFE2L2 Mutations on Local Recurrence in Patients Receiving Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases




Alex Gooding, MD, PhD • PQA 06 • September 30 • 5-6 p.m.

Unbiased Functional Genomics Screen Identifies Unique Therapeutic Vulnerabilities in Osimertinib-Resistant NSCLCs



Emily Harris, MD • PQA 03 • September 30 • 8-9 a.m.

Local Recurrence Rates following Equivocal 3-month Post-Treatment PET after High Dose Rate Brachytherapy for Locally Advanced Cervical Cancer: An Updated Cohort




Christina Huang, MD, MS • SS 27 • September 30 • 5-5:10 p.m.

Long-Term Update of a Phase 2 Study of Dose-Reduced Consolidation Radiation Therapy in Diffuse Large B-Cell Lymphoma



Abhishek Kumar, MD, MAS • PQA 08 • October 1 • 2:30-3:45 p.m.

Association of MRI Capsular Involvement and Extraprostatic Extension on Metastasis Free and Overall Survival in Localized Prostate Cancer Treated with Radiation



Dominic LaBella, MD • PQA 08 • October 1 • 2:30-3:45 p.m.

Efficacy of Oligometastasis Directed Stereotactic Body Radiation Therapy in De Novo Oligometastatic Prostate Cancer

PQA 08 • October 1 • 2:30-3:45 p.m.

Efficacy of Oligorecurrence Directed Stereotactic Body Radiation Therapy in Oligorecurrent Prostate Cancer



Jim Leng, MD • PQA 10 • October 2 • 10:30-11:45 a.m.

Cost Estimates of Brachytherapy Delivery in Northern Tanzania Using Time-Driven Activity Based Costing